Live from ClinicalTrials.gov + Open Targets, fetched 2026-11-12 09:06 UTC. Every row links to its source record.
Postmortem · what the sponsor and named sources said, kept apart from what merely happened at the same time
Lirilumab and Nivolumab With 5-Azacitidine in Patients With Myelodysplastic Syndromes (MDS)
NCT02599649 · M.D. Anderson Cancer Center · PHASE2 · terminated · last registry update 2020-01-14 · Decision brief
No research has been run for this trial yet, so only the registry's own reason and the timeline are shown.
What was said, and by whom
Stated is the sponsor's own words; Reported is a named third party. The category is our label from a fixed list; the quote is the evidence.
| Kind | Quote | Our category | Source |
|---|---|---|---|
| Stated | “Enrollment was stopped after the sponsor's decision not to pursue the development of lirilumab for myeloid malignancies.” | – | Registry record, M.D. Anderson Cancer Center |
Also happening at the time. Not shown to be a cause.
Registry events on other trials of drugs against KIR2DL1 within 12 months either side of this trial's last update, live from ClinicalTrials.gov. Nothing here was stated as a reason.
- 2020-05-26Results posted on the registry: M.D. Anderson Cancer Center, Lirilumab + Rituximab (NCT02481297)
- 2019-11-19Also stopped (terminated): National Cancer Institute (NCI), (Anti-KIR) (NCT01248455)
- 2019-09-24Results posted on the registry: M.D. Anderson Cancer Center, Azacitidine + Lirilumab (NCT02399917)
- 2019-09-24Also stopped (terminated): M.D. Anderson Cancer Center, Azacitidine + Lirilumab (NCT02399917)
- 2019-02-08Results posted on the registry: Innate Pharma, IPH2102 at 0.1 mg/kg + IPH2102 at 1 mg/kg (NCT01687387)
What is not public
- Internal portfolio and board discussions
- Unpublished trial data and interim analyses
- Terms of any partner or licence decision